Managing Partner Michael Abrams spoke with BioWorld about the FTC’s recently released interim report on harmful PBM practices and its plans to sue the three largest PBMs.

Abrams shared that the PBM conglomerates are self-dealing, and that targeting specific practices is a modest step and could be a challenge.

Trying to understand, let alone untangle, the thicket of arrangements and practices and processes behind this whole area requires the training of a forensic accountant.

Abrams also questioned the timing of the FTC report and why there hasn’t been more urgency to address these problems.

Read the full article at BioWorld (subscription required).